Cancer is a heterogeneous disease, meaning every tumour may addict to distinct oncogenic mechanisms and therefore need personalised treatment. This complexity could arise from genomic alterations (e.g. mutations), microenvironment changes (e.g. immune cells) and their interactions. Nevertheless, current therapeutic development mainly focuses on one of these alterations, resulting poor response in many cases.
Dr Haonan Lu was previously trained in bioinformatics and cell biology at Imperial College London. He is particularly interested in developing imaging-based methods to describe cancer phenotypes, as well as discovering novel therapeutic targets through functional genomics approach.
et al., 2021, Consideration of metabolite efflux in radiolabelled choline kinetics, Pharmaceutics, ISSN:1999-4923
et al., 2021, Novel non-congeneric derivatives of the choline kinase alpha inhibitor ICL-CCIC-0019, Pharmaceutics, Vol:13, ISSN:1999-4923, Pages:1-17
et al., 2021, Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer, British Journal of Cancer, Vol:124, ISSN:0007-0920, Pages:1286-1293
et al., 2021, Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma, Nature Communications, Vol:12, ISSN:2041-1723
et al., 2021, The Oxford Classic links epithelial-to-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers, Clinical Cancer Research, Vol:27, ISSN:1078-0432, Pages:1570-1579